An international expert panel, active within the European Society for Blood and Marrow
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …

Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation
(HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with …

This is the sixth special report that the European Society for Blood and Marrow
Transplantation regularly publishes on the current practice and indications for …

Defining conditioning regimen intensity has become a critical issue for the hemopoietic stem
cell transplant (HSCT) community. In the present report we propose to define conditioning …

Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk
haematological malignant disorders and other life-threatening haematological and genetic …

Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative
conditioning regimen (MAC) before allogeneic transplantation in patients with …

This review gives an account of the clinical and hematologic features of the myelodysplastic
syndromes. It supplies the latest classification of these disorders, discusses the cytogenetic …

Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …

Purpose Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)
primarily afflict older individuals. Hematopoietic cell transplantation (HCT) is generally not …